Genome-edited Allogeneic Donor "universal" Chimeric Antigen Receptor T Cells

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2022 Oct 12

PMID 36223560

Authors

Waseem Qasim

Affiliations

Soon will be listed here.

Abstract

αβ T cell receptor (TCRαβ) T cells modified to express chimeric antigen receptors (CAR), are now available as authorized therapies for certain B-cell malignancies. However the process of autologous harvest and generation of patient-specific products is costly, with complex logistics and infrastructure requirements. Premanufactured banks of allogeneic donor-derived CAR T cells could help widen applicability if the challenges of HLA-mismatched T-cell therapy can be addressed. Genome editing is being applied to overcome allogeneic barriers, most notably, by disrupting TCRαβ to prevent graft-versus-host disease, and multiple competing editing technologies, including CRISPR/Cas9 and base editing, have reached clinical phase testing. Improvements in accuracy and efficiency have unlocked applications for a wider range of blood malignancies, with multiplexed editing incorporated to target HLA molecules, shared antigens and checkpoint pathways. Clinical trials will help establish safety profiles and determine the durability of responses as well as the role of consolidation with allogeneic transplantation.

Citing Articles

Engineered Cellular Therapies for the Treatment of Thoracic Cancers.

Erickson S, Manning B, Kumar A, Patel M Cancers (Basel). 2025; 17(1.

PMID: 39796666 PMC: 11718842. DOI: 10.3390/cancers17010035.

CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?.

Rangel-Pelaez C, Martinez-Gutierrez L, Tristan-Manzano M, Callejas J, Ortego-Centeno N, Martin F Front Immunol. 2025; 15:1502712.

PMID: 39742256 PMC: 11685126. DOI: 10.3389/fimmu.2024.1502712.

Allogeneic chimeric antigen receptor cell therapies for cancer: progress made and remaining roadblocks.

Diorio C, Teachey D, Grupp S Nat Rev Clin Oncol. 2024; 22(1):10-27.

PMID: 39548270 DOI: 10.1038/s41571-024-00959-y.

CRISPR-Cas9 in basic and translational aspects of cancer therapy.

Samareh Salavatipour M, Poursalehi Z, Hosseini Rouzbahani N, Mohammadyar S, Vasei M Bioimpacts. 2024; 14(6):30087.

PMID: 39493894 PMC: 11530967. DOI: 10.34172/bi.2024.30087.

Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy.

Lei T, Wang Y, Zhang Y, Yang Y, Cao J, Huang J Leukemia. 2024; 38(12):2517-2543.

PMID: 39455854 PMC: 11588664. DOI: 10.1038/s41375-024-02444-y.

References

Ren J, Zhang X, Liu X, Fang C, Jiang S, June C . A versatile system for rapid multiplex genome-edited CAR T cell generation. Oncotarget. 2017; 8(10):17002-17011. PMC: 5370017. DOI: 10.18632/oncotarget.15218. View

Schober K, Muller T, Gokmen F, Grassmann S, Effenberger M, Poltorak M . Orthotopic replacement of T-cell receptor α- and β-chains with preservation of near-physiological T-cell function. Nat Biomed Eng. 2019; 3(12):974-984. DOI: 10.1038/s41551-019-0409-0. View

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D . Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019; 380(18):1726-1737. PMC: 8202968. DOI: 10.1056/NEJMoa1817226. View

Montini E, Cesana D, Schmidt M, Sanvito F, Ponzoni M, Bartholomae C . Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration. Nat Biotechnol. 2006; 24(6):687-96. DOI: 10.1038/nbt1216. View

Benjamin R, Graham C, Yallop D, Jozwik A, Mirci-Danicar O, Lucchini G . Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies. Lancet. 2020; 396(10266):1885-1894. PMC: 11773457. DOI: 10.1016/S0140-6736(20)32334-5. View

Ruella M, Xu J, Barrett D, Fraietta J, Reich T, Ambrose D . Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med. 2018; 24(10):1499-1503. PMC: 6511988. DOI: 10.1038/s41591-018-0201-9. View

Maude S, Laetsch T, Buechner J, Rives S, Boyer M, Bittencourt H . Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018; 378(5):439-448. PMC: 5996391. DOI: 10.1056/NEJMoa1709866. View

Berdeja J, Madduri D, Usmani S, Jakubowiak A, Agha M, Cohen A . Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study. Lancet. 2021; 398(10297):314-324. DOI: 10.1016/S0140-6736(21)00933-8. View

Georgiadis C, Rasaiyaah J, Gkazi S, Preece R, Etuk A, Christi A . Base-edited CAR T cells for combinational therapy against T cell malignancies. Leukemia. 2021; 35(12):3466-3481. PMC: 8632682. DOI: 10.1038/s41375-021-01282-6. View

10.

Sharma P, Kanapuru B, George B, Lin X, Xu Z, Bryan W . FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. Clin Cancer Res. 2022; 28(9):1759-1764. PMC: 9064878. DOI: 10.1158/1078-0432.CCR-21-3803. View

11.

Webber B, Lonetree C, Kluesner M, Johnson M, Pomeroy E, Diers M . Highly efficient multiplex human T cell engineering without double-strand breaks using Cas9 base editors. Nat Commun. 2019; 10(1):5222. PMC: 6864045. DOI: 10.1038/s41467-019-13007-6. View

12.

Hacein-Bey-Abina S, Garrigue A, Wang G, Soulier J, Lim A, Morillon E . Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008; 118(9):3132-42. PMC: 2496963. DOI: 10.1172/JCI35700. View

13.

Coles A, Compston A . Product licences for alemtuzumab and multiple sclerosis. Lancet. 2014; 383(9920):867-8. DOI: 10.1016/S0140-6736(14)60440-2. View

14.

Kamiya T, Wong D, Png Y, Campana D . A novel method to generate T-cell receptor-deficient chimeric antigen receptor T cells. Blood Adv. 2018; 2(5):517-528. PMC: 5851418. DOI: 10.1182/bloodadvances.2017012823. View

15.

Scholler J, Brady T, Binder-Scholl G, Hwang W, Plesa G, Hege K . Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells. Sci Transl Med. 2012; 4(132):132ra53. PMC: 4368443. DOI: 10.1126/scitranslmed.3003761. View

16.

Pan J, Tan Y, Wang G, Deng B, Ling Z, Song W . Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I Trial. J Clin Oncol. 2021; 39(30):3340-3351. DOI: 10.1200/JCO.21.00389. View

17.

Ott M, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U . Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med. 2006; 12(4):401-9. DOI: 10.1038/nm1393. View

18.

Nissani A, Lev-Ari S, Meirson T, Jacoby E, Asher N, Ben-Betzalel G . Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy. J Immunother Cancer. 2021; 9(5). PMC: 8127974. DOI: 10.1136/jitc-2020-001743. View

19.

Petri K, Zhang W, Ma J, Schmidts A, Lee H, Horng J . CRISPR prime editing with ribonucleoprotein complexes in zebrafish and primary human cells. Nat Biotechnol. 2021; 40(2):189-193. PMC: 8553808. DOI: 10.1038/s41587-021-00901-y. View

20.

Melenhorst J, Chen G, Wang M, Porter D, Chen C, Collins M . Decade-long leukaemia remissions with persistence of CD4 CAR T cells. Nature. 2022; 602(7897):503-509. PMC: 9166916. DOI: 10.1038/s41586-021-04390-6. View